InnotiveDx Achieves Major Funding Milestone
Innotive Diagnostics, known as InnotiveDx, is thrilled to announce a significant achievement that promises to revolutionize the diagnosis of urinary tract infections (UTIs). The company has secured a £1 million grant from PACE (Pathways to Antimicrobial Clinical Efficacy), designed to support innovative developments in the healthcare sector.
Importance of UTI Diagnostics
Every year, UTIs impact countless individuals worldwide, leading to more than 20% of all antibiotic prescriptions. This staggering statistic highlights an urgent call for effective antimicrobial stewardship, as improper treatment options can contribute significantly to the growing problem of antimicrobial resistance (AMR). Unaddressed, this situation not only endangers public health but also places extensive financial burdens on healthcare systems globally.
Innovative Technology Introduction
InnotiveDx has engineered a cutting-edge diagnostic technology that delivers rapid results, effectively identifying bacterial pathogens and determining antimicrobial susceptibility in less than an hour. With a proven accuracy rate exceeding 96%, the potential of this technology is enormous. Currently, the system is transitioning into automated prototypes, ready for further validation through the support of the newly acquired grant.
The Benefit of Grant Funding
The PACE grant will facilitate comprehensive testing of InnotiveDx’s prototypes against thousands of clinical specimens. This step is crucial for validating the system's effectiveness before embarking on a real-world clinical pilot study. The funding represents not just a financial boost but also serves as a recognition of the remarkable potential inherent in InnotiveDx’s work.
Leadership Insights
James Mainwaring, the Chief Commercial and Operating Officer of InnotiveDx, expressed his enthusiasm about the grant, stating, "This funding signifies a remarkable endorsement of our technology and vision. Our team's hard work since the company’s inception has been unwavering, and we are excited to collaborate with PACE in tackling the pressing challenges posed by AMR." His sentiments echo a commitment to remaining at the forefront of innovative healthcare solutions.
A PACE Collaboration
Dr. Beverley Isherwood, the Programme Director of PACE, also shared her excitement about welcoming InnotiveDx into their portfolio. She stated, "We are thrilled to assist InnotiveDx in advancing their diagnostic capabilities through a collaborative approach, enabling them to gather essential validation data and reshape their project for future growth and funding opportunities". This reflects the collaborative spirit within the innovative health ecosystem, aimed at delivering impactful solutions for pressing healthcare issues.
About InnotiveDx
InnotiveDx, a pioneering in-vitro diagnostics company, is reshaping how healthcare professionals diagnose UTIs. Their breakthrough InnotiveUTI test promises to offer rapid diagnosis and provide comprehensive bacterial identification and antimicrobial susceptibility results within a mere 60 minutes right at the point of care, addressing a critical gap in current medical practices.
About PACE
PACE, or Pathways to Antimicrobial Clinical Efficacy, stands as one of the UK's largest public-private initiatives. This collaboration emphasizes the importance of fostering development in early-stage antimicrobial drugs and diagnostic methods. The partnership includes key entities such as Innovate UK, LifeArc, and the Medicines Discovery Catapult, all committed to enhancing healthcare through innovation.
Frequently Asked Questions
What is the purpose of the £1 million grant awarded to InnotiveDx?
The grant aims to support InnotiveDx in developing its rapid urinary tract infection diagnostic system and validating its prototypes.
How does the InnotiveUTI test work?
The InnotiveUTI test provides rapid bacterial identification and antimicrobial susceptibility results within 60 minutes at the point of care.
Why are UTIs a concern for public health?
UTIs affect millions annually, contributing significantly to antibiotic prescriptions and the broader issue of antimicrobial resistance.
What are the expected outcomes of the collaboration with PACE?
The collaboration aims to generate essential validation data, facilitating further development and investment for InnotiveDx’s diagnostic solutions.
Who are the key players involved in the PACE initiative?
PACE is a collaboration involving Innovate UK, LifeArc, and the Medicines Discovery Catapult, focused on advancing antimicrobial therapy and diagnostics.
